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Abstract Hereditary endocrine diseases are an important
group of diseases with great heterogeneity. The current
classification for hereditary endocrine disease is mostly
based upon anatomy, which is helpful for pathophysio-
logical interpretation, but does not address the pathogenic
variability associated with different underlying genetic
causes. Identification of an endocrinopathy-associated
genetic alteration provides evidence for differential diag-
nosis, discovery of non-classical disease, and the potential
for earlier diagnosis and targeted therapy. Molecular
diagnosis should be routinely applied when managing
patients with suspicion of hereditary disease. To enhance
the accurate diagnosis and treatment of patients with
hereditary endocrine diseases, we propose categorization of
endocrine diseases into three groups based upon the func-
tion of the mutant gene: cell differentiation, hormone
synthesis and action, and tumorigenesis. Each category was
further grouped according to the specific gene function. We
believe that this format would facilitate practice of preci-
sion medicine in the field of hereditary endocrine diseases.
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Introduction
Since Vaughan Pendred first described Pendred Syndrome
in 1896 [1], there have been approximately 200 hereditary
endocrine diseases recorded in OMIM database. A recently
published consensus of rare endocrine–metabolic diseases
(REMD) [2] identified a disease taxonomy that comprised
a total of 166 main disorders, which grew to 338 when all
variants and subtypes were included. Because of this great
heterogeneity, accurate diagnosis remains a challenge for
endocrinologists. Importantly, *90 % of described endo-
crine syndromes have a defined underlying genetic cause
that would allow for definitive diagnosis. Currently, diag-
nosis is largely based on an anatomical classification,
where the specific endocrine gland(s) or involved cell type
serve as primary route to disease identification [3].
Unfortunately, anatomical location alone only partially
addresses the pathophysiological mechanism of the dis-
ease. The lack of a molecular picture clearly limits a
comprehensive understanding of physiological pathogene-
sis and sometimes leads to errors in diagnosis, as well as,
suboptimal treatment. An expanding literature continues to
define clear genotype/phenotype correlations, which work
to efficiently guide clinical diagnosis, treatment, and
prognosis. For hereditary endocrine diseases that clinically
show overlap (e.g., mesenchymal tumor in MEN1 and
TSC), uncovering the unique genetic basis provides abso-
lute clarity in the differential diagnosis [3]. The other
obvious advantage of genetic testing is the opportunity for
uncovering multiple sites involvement in syndromic dis-
orders. For example, hyperparathyroidism with germline
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MEN1 mutation obligates screening of pituitary, pancreas,
and gastrointestinal tract for potential tumorigenesis [4].
Numerous additional examples exist where genetic diag-
nosis plays a key role in guiding diagnosis and appropriate
treatment. Thus, we strongly believe that the current
anatomical classification should be supplemented with an
approach that includes molecular genotyping.
Currently, over 300 genes have been identified as targets
for causal mutations in hereditary endocrine diseases.
Advances in DNA sequencing have continued to expand the
breadth of genes at an ever-reducing cost. We are quickly
approaching a point where molecular diagnosis should be
routinely applied when managing patients with hereditary
disease. As a result, the use of molecular classification
needs to be reconsidered. In fact, the concept of using
molecular classification for hereditary endocrine disease
was proposed a decade ago by Prof. Marx [3]. The purpose
of this manuscript is to describe a molecular classification to
serve as basis for classification of hereditary endocrine
disease. The molecular classification is based upon the
biological function of the mutated genes. As shown in
Table 1, we recommend three broad categories: cell dif-
ferentiation, hormone synthesis/action, and tumoriogenesis.
A discussion of the rationale for the three categories and
examples of genes that would fall into each group follows.
Category of cell differentiation
Specific cell lineage development and differentiation is
the first step in constructing a functional endocrine sys-
tem. This process involves complex spatiotemporal
regulation of cell lineage–specific transcription factors
expressed in pluripotential stem cells. A genetic abnor-
mality involving any of these key transcription factors is
an important cause of congenital dysgenesis or agenesis.
Specific examples of dysgenesis exist for all major
endocrine glands including pituitary, thyroid, pancreas,
adrenals, and gonads. It is also clear that multiple genes
may have similar effects on a single gland; for example,
loss of PAX8, FOXE1, and NKX2-1 is associated with
thyroid gland dysgenesis [5]. Additionally, single gene
defects may impact multiple glands. DAX1 is essential
for both adrenal and gonad development. Mutation in
DAX1 led to adrenal hypoplasia congenita (AHC) and
hypogonadotropic hypogonadism (HH) [6]. Currently,
treatment for this category of disease is hormone
replacement in the lifetime. In the future, generation of
functional endocrine gland from embryonic stem cells
may be new avenue [7].
Category of hormone synthesis/action
The two broad classes of hormones include peptide hor-
mones and non-peptide hormones. Peptide hormones are
directly translated from an encoding gene and therefore
venerable to direct mutation. Genetic defects in an
encoding gene (e.g., AVP) typically lead to complete loss
of function, impaired function, or failures in post-transla-
tion processing of peptide hormone [8]. Mutation of genes
in this category usually leads to solitary hormone defi-
ciency (e.g., autosomal dominant neurohypophyseal dia-
betes insipidus) [8].
Table 1 Molecular classification of hereditary endocrine diseases
Category Sub-category e.g. Associated diseases Tissue




AHC&HH Adrenal and pituitary
Hormone synthesis
and action




Genes encoding transporter for
synthetic materials














Genes encoding ion channel SCN4A Liddle syndrome Kidney
Tumoriogenesis Oncogene RET MEN2 Thyroid C cell/adrenal
medulla/parathyroid and etc
Tumor suppressor gene MEN1 MEN1 Parathyroid/islet/pituitary and etc.
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Non-peptide hormones are synthesized by a series of
synthetic enzymes from natural materials. Therefore,
mutation targeting is indirect. Steroid hormones represent
the single most important group of non-peptide hor-
mones. They are all derived from cholesterol and
therefore share a complex synthetic pathway. Through
the concerted action of several enzymes, such as
CYP21A2, CYP17A1, CYP11B1, HSD3B2, etc., multiple
steroid hormones are produced, degraded, and recycled.
For this reason, mutations targeting these genes often
have complex phenotypic outcomes, such as congenital
adrenal hyperplasia (CAH) [9]. Importantly, mutations
targeting early steps of the synthetic pathway effect
production of multiple steroids.
In addition to synthesis, the appropriate transportation of
synthetic materials is indispensable for non-peptide hor-
mones as well. This gene class when targeted by mutation
may lead to impaired hormone synthesis/function.
SLC26A4, for example, encodes an iodide chloride trans-
porter that resides in thyroid follicular cells, known as
pendrin. Mutated pendrin is retained in the endoplasmic
reticulum instead of being trafficked to plasma membrane,
therefore decreasing iodide transport, causing hypothy-
roidism in Pendred syndrome [10].
To respond to a hormone, a target cell must contain two
essential components of a signaling pathway: a function
receptor and effector. Hormone receptors mainly include
two groups, membrane receptor and nuclear receptor.
Inactivating mutations in hormone receptors either cause
hormone resistance phenotypically or mimic hormone
insufficiency, while activated mutations cause hormone
hypersensitivity. Insulin receptor (INSR) and glucocorti-
coid receptor (GR) are ubiquitously expressed membrane
and nuclear receptor, respectively. Activating mutations
cause familial hyperinsulinemic hypoglycemia [11] and
glucocorticoid hypersensitivity [12], while inactivating
mutations cause insulin resistant syndrome [13] and glu-
cocorticoid resistance, respectively [14].
Effectors mainly include signaling molecules and some-
times ion channels as the terminal effector. Post-receptor sig-
naling molecules are mostly downstream of cell membrane
receptor and serve a critical role in the intracellular messaging.
A well-characterized example involves G protein–coupled
receptors (GPCR). GPCRs transduce extracellular signals to
hormone-sensitive adenylate cyclase, the activity of which is
regulated by at least 2 G proteins, 1 stimulatory (Gs), and 1
inhibitory (Gi) [15]. Gs-a is encoded by GNAS and activating
mutations of GNAS gene result in constitutively active GPCR
and clinicallyMcCune-Albright syndrome, polyostotic fibrous
dysplasia, and various endocrine tumors [16]. Inactivating loss-
of-function mutations, on the other hand, result in loss of
function of GPCR and clinically pseudohypoparathyroidism Ia
(PHP1A), pseudopseudohypoparathyroidism (PPHP), and
progressive osseous heteroplasia (POH) [17].
Ion channels are important effectors in mediating min-
eralocorticoids function. Integrated synthesis and function
of ion channels are indispensable in maintaining salt
homeostasis. Mutations in either the beta subunit
(SCNN1B) or the gamma subunit (SCNN1G) cause con-
stitutive activation of the renal epithelial sodium channel
(ENaC) [18]. Clinically, patients with these mutations
present with inappropriate K? excretion and hypokalemia
(Liddle syndrome) [18].
Diseases targeting hormone function may clinically
present as either gain or loss of function. For this reason,
we include specific sub-categories related to the molecular
functions. The categorization of a specific genetic defect
occurring in the hormone pathway helps guide optimal
treatment. For example, identification of a defective sig-
naling pathway rather than lack of hormone triggers a
completely different treatment route, as supplementation
becomes a less viable option.
Category of tumoriogenesis
Tumor syndromes are described for all major endocrine
glands, and like other cancers have been linked to acti-
vating mutations of oncogenes or inactivating mutations of
tumor suppressor genes. Perhaps the best-described
examples are activating mutations of RET proto-oncogene
in MEN2 [19] and inactivating mutations of MEN1 tumor
suppressor gene in MEN1 [20]. Germline RET mutations
cause constitutive activation of the RET kinase and
downstream signaling pathway, therefore leading to
uncontrolled cell proliferation. Targeting RET has opened
a new treatment practice in advanced medullary thyroid
carcinoma [21]. On the other hand, the germline inactiva-
tion of MEN1 requires a ‘second hit’ of the remaining wild
type allele to initiate tumorigenesis. While this risk exists
in all tissues, the clinical impact is greatest in the
parathyroid, pituitary, and pancreas. Tumoriogenesis is a
category where genetic testing has a proven benefit that
extends well beyond endocrine syndromes. Knowledge of
specific mutation status guides treatment of asymptomatic
endocrine glands in patients and their relatives before they
anatomically identified. Where cancer has progressed,
identification of mutational drivers provides the opportu-
nity for targeted therapy.
The benefits derived from defining a molecular classi-
fication should be integrated with clinical diagnosis.
Accurate clinical diagnosis including defining the specific
hormone disorder and localizing the disease lesion is a
fundamentally important component of clinical care.
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Genetic diagnosis provides a means of definitive diagnosis,
thereby outlining an accurate treatment strategy for the
patient and family members potentially at risk. We are now
in a period of transition when genetics is creating the
opportunity for a new level of personalized medicine.
Recently, President Obama launched the project of Preci-
sion Medicine Initiative [22, 23]. While significant
advances in precision medicine have been made for select
cancers [24], the practice is not currently in use for most
diseases, including hereditary endocrine disease. The con-
cept of precision medicine should start with known can-
didate genes. We believe that as genetic analysis becomes
more recognized for its role in patient management, there is
value in stratifying mutations by molecular category.
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